目的 评价奥利司他治疗非酒精性脂肪性肝病的效果。方法 从PubMed、Web of Science、中国知网、中国生物医学文献数据库、维普数据库和万方数据知识服务平台数据库检索从建库开始至2023年9月国内外关于奥利司他治疗非酒精性脂肪性肝病的文献。运用Review Manager 5。4。1进行Meta分析。结果 研究共纳入8篇文献，共450例患者，纳入研究无发表偏倚。Meta分析结果显示，研究组患者为丙氨酸转氨酶(ALT)[MD=-35。18，95％CI(-56。71，-13。64)，P＜0。01]，天冬氨酸转氨酶(AST)(MD=-25。69，95％CI(-43。13，-8。26)，P＜0。01]，谷氨酰转移酶(GGT)[MD=-48。12，95％CI(-74。65，-21。60)，P＜0。01]，总胆固醇[MD=-2。13，95％CI(-4。06，-0。21)，P=0。03]，三酰甘油[MD=-2。20，95％CI(-4。21，-0。19)，P=0。03]水平低于对照组，差异均具有统计学意义。结论 奥利司他治疗非酒精性脂肪性肝病可有效降低患者ALT、AST、GGT、总胆固醇及三酰甘油水平。
Meta analysis of the efficacy of orlistat in the treatment of non-alcoholic fatty liver disease
Objective To evaluate the efficacy of orlistat in the treatment of nonalcoholic fatty liver disease.Methods PubMed,Web of Science,CNKI,China Biomedical Literature Database,Weipu Database and Wanfang Data Knowledge Service Platform Database were searched from the establishment of the library to September 2023 on orlistat in the treatment of non-alcoholic fatty liver disease.Meta-analysis was performed using Review Manager 5.4.1.Results Eight studies with a total of 450 patients were included in the study,and there was no publication bias in the included studies.The results of Meta-analysis showed that patients in the experi-mental group had ALT[MD=-35.18,95％CI(-56.71,-13.64),P＜0.01],AST[MD=-25.69,95％CI(-43.13,-8.26),P＜0.01],GGT[MD=-48.12,95％CI(-74.65,-21.60),P＜0.01],total cholesterol[MD=-2.13,95％CI(-4.06,-0.21),P=0.03],triglyceride[MD=-2.20,95％CI(-4.21,-0.19),P=0.03]levels were lower than those in the control group with statistically significant.Conclusion Orlistat can effectively treat non-alcoholic fatty liver disease and effectively reduce ALT,AST,GGT,total cholesterol and triglyceride levels.
万方数据
维普
